Other Species / Isoforms
  CDC42EP3 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
Y8-p
MPAKTPIyLkAANNk
0 1
CDC42EP3 (human) MPAKTPIyLkAANNk Y8-p
CDC42EP3 (mouse) MPAKTPIYLKAANNK Y8
CDC42EP3 (rat) MPAKTPIYLKAANNK Y8
K10-m1
AKTPIyLkAANNkKG
0 1
CDC42EP3 (human) AKTPIyLkAANNkKG K10-m1
CDC42EP3 (mouse) AKTPIYLKAANNKKG K10
CDC42EP3 (rat) AKTPIYLKAANNKKG K10
K15-m1
yLkAANNkKGKKFKL
0 1
CDC42EP3 (human) yLkAANNkKGKKFKL K15-m1
CDC42EP3 (mouse) YLKAANNKKGKKFKL K15
CDC42EP3 (rat) YLKAANNKKGKKFKL K15
S27-p
FKLRDILsPDMIsPP
Upstream
0 4
Treatment
  • BI_4834
CDC42EP3 (human) FKLRDILsPDMIsPP S27-p
CDC42EP3 (mouse) FKLRDILSPDMISPP S27
CDC42EP3 (rat) FKLRDILSPDMISPP S27
S32-p
ILsPDMIsPPLGDFR
Upstream
0 5
Treatment
  • LRRK2-IN-1
CDC42EP3 (human) ILsPDMIsPPLGDFR S32-p
CDC42EP3 (mouse) ILSPDMISPPLGDFR S32
CDC42EP3 (rat) ILSPDMISPPLGDFR S32
Y63-p
ISFLQGNyELLPGNQ
0 5
CDC42EP3 (human) ISFLQGNyELLPGNQ Y63-p
CDC42EP3 (mouse) ISFLQGNYELLPGNQ Y63
CDC42EP3 (rat) ISFLQGNYELLPGNQ Y63
L75
GNQEKAHLGQFPGHN
0 4
CDC42EP3 (human) GNQEKAHLGQFPGHN L75
CDC42EP3 (mouse) GNQEKAHsGQFPGHN S75-p
CDC42EP3 (rat) GNQEKAHSGQFPGHN S75
S89-p
NEFFRANstsDsVFT
Upstream
0 54
Treatment
  • gefitinib
  • selumetinib
  • vemurafenib
CDC42EP3 (human) NEFFRANstsDsVFT S89-p
CDC42EP3 (mouse) NDFFRANstsDSMFT S89-p
CDC42EP3 (rat) NDFFRANsTSDSMFT S89-p
T90-p
EFFRANstsDsVFTE
0 12
CDC42EP3 (human) EFFRANstsDsVFTE T90-p
CDC42EP3 (mouse) DFFRANstsDSMFTE T90-p
CDC42EP3 (rat) DFFRANsTSDSMFTE T90
S91-p
FFRANstsDsVFTEt
0 9
CDC42EP3 (human) FFRANstsDsVFTEt S91-p
CDC42EP3 (mouse) FFRANstsDSMFTET S91-p
CDC42EP3 (rat) FFRANsTSDSMFTET S91
S93-p
RANstsDsVFTEtPs
0 1
CDC42EP3 (human) RANstsDsVFTEtPs S93-p
CDC42EP3 (mouse) RANstsDSMFTETPs S93
CDC42EP3 (rat) RANsTSDSMFTETPS S93
T98-p
sDsVFTEtPsPVLKN
0 3
CDC42EP3 (human) sDsVFTEtPsPVLKN T98-p
CDC42EP3 (mouse) sDSMFTETPsPVLKN T98
CDC42EP3 (rat) SDSMFTETPSPVLKN T98
S100-p
sVFTEtPsPVLKNAI
Upstream
0 22
Treatment
  • LRRK2-IN-1
  • selumetinib
  • vemurafenib
CDC42EP3 (human) sVFTEtPsPVLKNAI S100-p
CDC42EP3 (mouse) SMFTETPsPVLKNAI S100-p
CDC42EP3 (rat) SMFTETPSPVLKNAI S100
S108-p
PVLKNAIsLPTIGGS
Upstream
0 10
Treatment
  • LRRK2-IN-1
CDC42EP3 (human) PVLKNAIsLPTIGGS S108-p
CDC42EP3 (mouse) PVLKNAIsLPTIGGS S108-p
CDC42EP3 (rat) PVLKNAISLPTIGGS S108
S124-p
ALMLPLLsPVTFNSK
Upstream
0 3
Treatment
  • EGF
  • SB202190
CDC42EP3 (human) ALMLPLLsPVTFNSK S124-p
CDC42EP3 (mouse) ALMLPLLSPVTFHSK S124
CDC42EP3 (rat) ALMLPLLSPVTFNSK S124
S134
TFNSKQESFGPAkLP
0 2
CDC42EP3 (human) TFNSKQESFGPAkLP S134
CDC42EP3 (mouse) TFHSKQEsFGRPKLP S134-p
CDC42EP3 (rat) TFNSKQESFGRPKLP S134
K139-ub
QESFGPAkLPRLsCE
0 1
CDC42EP3 (human) QESFGPAkLPRLsCE K139-ub
CDC42EP3 (mouse) QEsFGRPKLPRLsCE K139
CDC42EP3 (rat) QESFGRPKLPRLSCE K139
S144-p
PAkLPRLsCEPVMEE
Upstream
0 13
Treatment
  • anti-CD3
  • ischemia
  • selumetinib
  • vemurafenib
CDC42EP3 (human) PAkLPRLsCEPVMEE S144-p
CDC42EP3 (mouse) RPKLPRLsCEPVMEE S144-p
CDC42EP3 (rat) RPKLPRLSCEPVMEE S144
S157-p
EEKAQEKsSLLENGt
0 1
CDC42EP3 (human) EEKAQEKsSLLENGt S157-p
CDC42EP3 (mouse) EEKVQEQSSLLENGA S157
CDC42EP3 (rat) EEKVEEKGSLLENGT G157
T164-p
sSLLENGtVHQGDTS
0 1
CDC42EP3 (human) sSLLENGtVHQGDTS T164-p
CDC42EP3 (mouse) SSLLENGAVHQGDTS A164
CDC42EP3 (rat) GSLLENGTVHQGDTS T164
T218-p
CELIKGKtKsEESLS
0 1
CDC42EP3 (human) CELIKGKtKsEESLS T218-p
CDC42EP3 (mouse) CELVKSKTKSEESFS T218
CDC42EP3 (rat) CELGKSKTKSEESLS T218
S220-p
LIKGKtKsEESLSDL
0 1
CDC42EP3 (human) LIKGKtKsEESLSDL S220-p
CDC42EP3 (mouse) LVKSKTKSEESFSDL S220
CDC42EP3 (rat) LGKSKTKSEESLSDL S220